Identification of miRNA biomarker signature for diagnosis and monitoring of lung diseases (ALLmiR-Study)

• Conditions: C34; J84; D86; R91; J44; Malignant neoplasm of bronchus and lung; Other interstitial pulmonary diseases; Sarcoidosis; Abnormal findings on diagnostic imaging of lung; Other chronic obstructive pulmonary disease

• Registration Number: DRKS00018784
• Lead Sponsor: Hummingbird Diagnostics GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-11-18
• Study Completion: 2023-07-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 1050

Inclusion Criteria

Male or female, =18 years old, Therapy naïve, Respiratory complaints, sufficient knowledge of German, Willingness to participate in study

Exclusion Criteria

Known infectious diseases (HIV, HCV, HBV), Advanced, curatively-treated cancer within last 5 years

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The aim is to evaluate a novel, miRNA-based method for the improvement of the diagnosis of lung diseases in a cohort of patients with lung complaints (all-comers).

Secondary Outcome Measures

Name	Time	Method
Identification of microRNA biomarker for safe and successful therapy and identification of microRNA biomarkers for relapse monitoring.